Tirzepatide vs Semaglutide for Weight Loss: 2026 Update

Semaglutide and tirzepatide have transformed the weight loss landscape. Both are injectable peptides that target the GLP-1 receptor system, but they work in fundamentally different ways — and the clinical data shows meaningfully different results.

Semaglutide (branded as Ozempic for type 2 diabetes and Wegovy for weight management) is a GLP-1 receptor agonist developed by Novo Nordisk. It mimics the natural hormone GLP-1 to reduce appetite, slow gastric emptying, and improve blood sugar control.

Tirzepatide (branded as Mounjaro for type 2 diabetes and Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It targets two incretin hormone receptors simultaneously — a key innovation that appears to deliver superior weight loss.

Both are administered as once-weekly subcutaneous injections. Both require a prescription in the UK for their pharmaceutical forms. And both have generated enormous demand and media attention.

The fundamental difference between these two peptides is their receptor targeting:

Semaglutide — GLP-1 Receptor Agonist Semaglutide activates only the GLP-1 receptor. When this receptor is activated, it: - Signals the brain to reduce appetite (hypothalamic satiety centres) - Slows gastric emptying, making you feel full longer - Stimulates insulin secretion in response to food - Reduces glucagon secretion (which lowers blood sugar) - The net effect is reduced food intake and improved metabolic function

Tirzepatide — Dual GIP/GLP-1 Receptor Agonist Tirzepatide activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The addition of GIP receptor activation provides: - Enhanced insulin sensitivity beyond what GLP-1 alone achieves - Improved fat metabolism and energy expenditure - Additional appetite suppression through complementary pathways - Better beta-cell function (the pancreatic cells that produce insulin) - Potentially greater weight loss due to the dual mechanism

Think of it this way: semaglutide pushes one powerful button, while tirzepatide pushes two complementary buttons simultaneously. The clinical data suggests this dual approach produces stronger results.

The clinical trial data is extensive for both peptides. Here's how they compare:

Semaglutide (STEP trials): - STEP 1: 16.9% average body weight loss at 68 weeks (2.4mg/week) - STEP 2: 9.6% weight loss in people with type 2 diabetes - STEP 3 (with lifestyle intervention): 16.0% weight loss - STEP 5 (2-year data): 15.2% sustained weight loss - Approximately 1 in 3 participants achieved ≥20% weight loss

Tirzepatide (SURMOUNT trials): - SURMOUNT-1: 22.5% average body weight loss at 72 weeks (15mg/week) - SURMOUNT-2: 14.7% weight loss in people with type 2 diabetes - SURMOUNT-3 (with lifestyle intervention): 26.6% weight loss - SURMOUNT-4 (maintenance): continued weight loss over 88 weeks - Over 1 in 3 participants achieved ≥25% weight loss at the highest dose

Head-to-head data: The SURPASS trials compared tirzepatide to semaglutide directly in type 2 diabetes patients: - Tirzepatide 15mg achieved 13.4kg weight loss vs 6.7kg for semaglutide 1mg - However, this compared the maximum tirzepatide dose to a sub-maximum semaglutide dose

The verdict: Tirzepatide appears to produce greater average weight loss than semaglutide, likely due to its dual-agonist mechanism. However, individual responses vary significantly, and both produce clinically meaningful results.

Both peptides share similar gastrointestinal side effects, which are the most commonly reported:

Common side effects (both): - Nausea (most common, especially during dose escalation) - Vomiting - Diarrhoea - Constipation - Abdominal pain - Decreased appetite (which is partly how they work)

Semaglutide-specific considerations: - Nausea reported in ~44% of participants in STEP trials - Generally milder at lower starting doses (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg escalation) - Rare reports of pancreatitis and gallbladder issues - Thyroid C-cell tumour risk (observed in rodents, unclear relevance to humans)

Tirzepatide-specific considerations: - Nausea reported in ~31% at the highest dose in SURMOUNT trials (slightly lower rate than semaglutide) - Dose escalation: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg - Similar rare risks (pancreatitis, gallbladder issues) - Some reports of injection site reactions

GI tolerability: Both peptides cause GI side effects, but slow dose escalation significantly reduces severity. Most side effects diminish after the first few weeks at each dose level. Tirzepatide may have a slightly better GI tolerability profile, but this varies between individuals.

Serious risks (both): Pancreatitis, gallbladder disease, and potential thyroid concerns are rare but documented risks. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma.

Semaglutide: - Ozempic (0.25mg, 0.5mg, 1mg) — available on NHS and private prescription for type 2 diabetes - Wegovy (0.25mg–2.4mg) — available on NHS (restricted criteria) and private clinics for weight management - Supply has stabilised in 2026 after previous shortages - Private clinic cost: approximately £150-300/month depending on dose and provider

Tirzepatide: - Mounjaro (2.5mg–15mg) — approved by MHRA for type 2 diabetes and weight management - Available on NHS (restricted criteria) and through private clinics - Supply still scaling up in the UK market - Private clinic cost: approximately £200-400/month depending on dose

Research-grade versions: Both peptides are available from research peptide suppliers at significantly lower cost than pharmaceutical versions. However, research-grade products: - Are not manufactured to pharmaceutical GMP standards - Are sold for research purposes only - May differ in purity and formulation from approved medicines - Should be verified via third-party Certificates of Analysis

NHS access: Both peptides are available on the NHS but typically require meeting specific BMI and comorbidity criteria. Waiting lists and local commissioning decisions affect access. Private clinics offer faster access but at significant ongoing cost.

The choice between tirzepatide and semaglutide depends on the research context:

Choose semaglutide if: - You want the largest existing evidence base (more published trials and longer post-market data) - The research focuses specifically on GLP-1 pathway mechanisms - Cost is a primary consideration (generally slightly cheaper) - Studying cardiovascular outcomes (semaglutide has dedicated CV outcome trial data — SELECT trial)

Choose tirzepatide if: - Maximum weight loss efficacy is the research priority - The research involves dual-agonist mechanisms (GIP + GLP-1) - Better GI tolerability is important for the study design - Studying insulin sensitivity and beta-cell function

The emerging contender — Retatrutide: Worth noting that retatrutide, a triple agonist (GIP/GLP-1/glucagon), has shown even greater weight loss in Phase II trials (up to 24% at 48 weeks). If approved, it could surpass both semaglutide and tirzepatide. Read our full retatrutide profile for the latest data.

For a comprehensive comparison, see our detailed Semaglutide vs Tirzepatide comparison page, which includes mechanism diagrams, head-to-head trial data, and a full safety comparison table.